Références[1] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.[2] Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2020.[3] Wichmann, D., et al., Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med, 2020.[4] Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, Ferraz da Silva LF, Pierre de Oliveira E, Nascimento Saldiva PH, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020.

23

Références

24

[5] Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohortstudy. Intensive Care Med. 2020.[6] Leonard-Lorant I, Delabranche X, Severac F, Helms J, Pauzet C, Collange O, et al. Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels. Radiology. 2020:201561.[7] Poyiadi N, Cormier P, Patel PY, Hadied MO, Bhargava P, Khanna K, et al. Acute Pulmonary Embolism and COVID-19. Radiology. 2020:201955.[8] Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020.

Références

25

[9] Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020.[10] Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J ThrombHaemost. 2020.[11] Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14.[12] Ren B, Yan F, Deng Z, Zhang S, Xiao L, Wu M, et al. Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients with Severe COVID-19 in Wuhan. Circulation. 2020.[13] Thomas W, Varley J, Johnston A, Symington E, Robinson M, Sheares K, et al. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. Thromb Res. 2020;191:76-7.

Références

26

[14] Bargellini I, Cervelli R, Lunardi A, Scandiffio R, Daviddi F, Giorgi L, et al. Spontaneous

Bleedings in COVID-19 Patients: An Emerging Complication. Cardiovasc Intervent Radiol. 2020

[15] Conti CB, Henchi S, Coppeta GP, Testa S, Grassia R. Bleeding in COVID-19 severe

pneumonia: The other side of abnormal coagulation pattern? Eur J Intern Med. 2020.

[16] Heman-Ackah SM, Su YS, Spadola M, Petrov D, Chen HI, Schuster J, et al. Neurologically

Devastating Intraparenchymal Hemorrhage in COVID-19 Patients on Extracorporeal Membrane

Oxygenation: A Case Series. Neurosurgery. 2020.

[17] Joob B, Wiwanitkit V. Hemorrhagic Problem Among the Patients With COVID-19:

Clinical Summary of 41 Thai Infected Patients. Clin Appl Thromb Hemost.

2020;26:1076029620918308.

Références[18] Agnes Lee Md, Menaka Pai, Menno Huisman, Stephan Moll, and Walter Ageno. COVID-19 and Pulmonary Embolism: Frequently Asked Questions. 2020.*Voir précision à la fin de ce document

[19] Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-6.

[20] Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020.

[21] Argulian E, Sud K, Vogel B, Bohra C, Garg VP, Talebi S, et al. Right Ventricular Dilation in Hospitalized Patients with COVID-19 Infection. JACC Cardiovasc Imaging. 2020.

27

Références[22] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated withdecreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J ThrombHaemost. 2020;18(5):1094-9.

28

COVID-19 and Pulmonary Embolism: Frequently Asked Questions (Version 2.0; last updated May 18, 2020

▸ In cases where there are no contraindications for therapeutic anticoagulation and there is no possibility of performing imaging studies to diagnose PE or DVT, empiric anticoagulation has been proposed in the following scenarios:▹ Intubated patients who develop sudden clinical and laboratory findings highly

consistent with PE, such as desaturation, tachycardia, increased CVP or PA wedge pressure, or evidence of right heart strain on echocardiogram, especially when CXR and/or markers of inflammation are stable or improving.

▹ Patients with physical findings consistent with thrombosis, such as superficial thrombophlebitis, peripheral ischemia or cyanosis, thrombosis of dialysis filters, tubing or catheters, or retiform purpura (branching lesions caused by thrombosis in the dermal and subcutaneous vasculature).

29

COVID-19 and Pulmonary Embolism: Frequently Asked Questions (Version 2.0; last updated May 18, 2020

▸ In cases where there are no contraindications for therapeutic anticoagulation and there is no possibility of performing imaging studies to diagnose PE or DVT, empiric anticoagulation has been proposed in the following scenarios:▹ Patients with respiratory failure, particularly when D-dimer

and/or fibrinogen levels are very high, in whom PE or microvascular thrombosis is highly suspected and other causes are not identified (e.g., ARDS, fluid overload).

30